Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ambroxol for Diabetic Peripheral Neuropathy
NCT05558878Unknown
- Sponsor
- Ain Shams University
- Start
- Oct 2022
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of Ambroxol hydrochloride oral solution in diabetic peripheral neuropathy (DPN) (2 arms), sponsored by Ain Shams University. Primary endpoints: Tumor Necrosis Factor alpha at 3 months, Nuclear Factor kappa-light-chain-enhancer of activated B cells at 3 months and 1 more. Status: unknown.
02
Drugs
Ambroxol hydrochloride oral solution
03
Conditions
diabetic peripheral neuropathy (DPN)
Beyond the preview
Go deeper on NCT05558878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05558878.